Cotización Arcus Biosciences - RCUS

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

16.235

Postura de Compra

Postura de Venta

Volume Operado de la Acción

183,877

15.63 Rango del Día 16.47

13.52 Rango de 52 semanas 20.31

Capitalización de Mercado [m]

1.486B

Precio Anterior

15.94

Precio de Apertura

15.90

Hora

16.235

Última hora de negociación

11:16:02

Volumen financiero

US$ 2,966,063

Precio Promedio Ponderado

16.1307

Volumen promedio (3 m)

726,959

Acciones en circulación

91,511,609

Rendimiento del Dividendo

Ratio Precio/Utilidad

-4.86

Beneficio por acción (BPA)

-3.35

turnover

117M

Beneficio neto

-307M

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.arcusbio.com

Sede

Camden, Delaware, USA

Fundado

Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was US$15.94. Over the last year, Arcus Biosciences shares have traded in a share price range of US$ 13.52 to US$ 20.31.

Arcus Biosciences currently has 91,511,609 shares in issue. The market capitalisation of Arcus Biosciences is US$1.46 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.86.

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising...

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36...

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Form 8-K - Current report

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	1.945	13.610916725	14.29	16.6	14.29	635798	15.78435435	CS
4	0.735	4.74193548387	15.5	18.98	14.15	778333	15.91466044	CS
12	0.035	0.216049382716	16.2	18.98	14.15	726959	16.50367054	CS
26	0.415	2.62326169406	15.82	18.98	13.52	703043	16.15346982	CS
52	0.195	1.21571072319	16.04	20.31	13.52	735730	16.63668831	CS
156	-29.355	-64.3891204211	45.59	47	12.95	870662	22.03401043	CS
260	8.395	107.079081633	7.84	49.1	7.69	740757	23.85148022	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
PSQHPSQ Holdings Inc	US$ 3.96 (92.23%)	76.97M
ATIPATI Physical Therapy Inc	US$ 2.37 (41.07%)	2.61M
BBAIBigBear ai Holdings Inc	US$ 2.58 (17.27%)	28.39M
CNMCore and Main Inc	US$ 55.755 (15.46%)	4.68M
LEVLion Electric Company	US$ 0.3302 (15.05%)	24.68M
TCSContainer Store Group Inc	US$ 1.9484 (-23.59%)	181.31k
MPLNChurchill Capital Corp III	US$ 6.7807 (-14.92%)	71.45k
CANGCango Inc	US$ 4.09 (-12.98%)	711.13k
NOTEFiscaNote Holdings Inc	US$ 0.9402 (-10.46%)	611.58k
LANVLanvin Group Holdings Limited	US$ 1.52 (-10.06%)	58.09k
PSQHPSQ Holdings Inc	US$ 3.96 (92.23%)	76.97M
NIONIO Inc	US$ 4.75 (7.95%)	44.8M
ACHRArcher Aviation Inc	US$ 6.865 (-5.96%)	36.12M
PCGPG&E Corporation	US$ 20.855 (1.48%)	34.55M
TAT&T Inc	US$ 23.6593 (4.23%)	31.29M